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Abstract
Non-small cell lung cancer (NSCLC) accounts for nearly 80% of diagnosed lung can-
cers. Due to the predominantly late diagnosis of NSCLC and drug resistance in the tar-
geted therapy approaches, the 5-year overall survival rate is still less than 19%. Thus, 
novel diagnosis and treatment approaches are needed. Many efforts have been made 
to achieve great progress in understanding the genomic landscape of NSCLC and the 
molecular mechanisms involved in tumorigenesis. Long non-coding RNAs (lncRNAs) 
are transcripts longer than 200 nucleotides with little or no protein-coding potential. 
They are encoded across the genome and are involved in a wide range of cellular and 
biological processes. Dysregulation of lncRNAs is associated with a number of cancer-
related processes, including epigenetic regulation, microRNA silencing, and DNA dam-
age. Furthermore, lncRNAs have been reported to have the potential as biomarker for 
diagnosis and prognosis, as well as the therapy targets. Here in this chapter, we review 
some well-characterized lncRNAs associated with NSCLCs and the potential of lncRNAs 
as biomarkers in the diagnosis and prognosis of NSCLCs.
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1. Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide. According to the esti-
mation of National Cancer Institute, USA, the estimated new cases for lung cancer in 2016 
will be 224,390, accounting 13.3% of all new cancer cases, and the estimated deaths of lung 
cancer in 2016 will be 158,080 accounting 26.5% of all new cancer cases [1]. Non-small cell 
lung cancer (NSCLC) is the most common type of lung cancer which accounts for nearly 
80–85% of diagnosed lung cancers [2]. NSCLC can be further histologically classified into 
three major subtypes: lung adenocarcinoma (ADC), lung squamous cell carcinoma (SCC), 
and large cell carcinoma. Much attention has been paid to the clinical diagnosis and treatment 
of NSCLC, however, the 5-year overall survival rate of NSCLC is still less than 19% in these 
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days [1]. This may attribute to the advanced stage of the disease at the time of diagnosis for 
many patients. The predominantly late diagnosis of NSCLC has limited the therapy options. 
The low-dose computed tomography (CT) scan can detect NSCLC early and has become the 
dominant detection approach. However, the high cost and the risk of false positive has over-
shadowed the benefits of swift diagnosis [3]. Thus, it is important to develop novel early 
detection approach with high sensitivity and specificity.
Biomarker is a powerful approach for cancer detection and treatment. It is defined as an indi-
cator of biologic processes, pathogenic processes, or pharmacologic responses to therapeutic 
interventions. Traditional protein biomarkers such as CEA, SSC, CY211, and CA125 are clas-
sic tumour biomarkers commonly used in the diagnoses of NSCLC patients [4]. However, the 
current lack of diagnostic sensitivity and specificity has limited their usefulness in early detec-
tion of NSCLC. The occurrence of NSCLC always comes with the genetic changes. A thorough 
understanding of the genetic aberrations that contribute to NSCLC would assist in identifying 
biomarkers that could aid in earlier diagnoses and serve as drug targets, thus increasing treat-
ment efficacy. Considerable efforts have been made to achieve great progress in understand-
ing genomic landscape of NSCLC and the molecular mechanisms involved in tumorigenesis, 
several cancer-related genes such as TP53, EGFR, and KRAS, have been identified which play 
a vital role in cancer-related pathways [5–7]. Identification and characterization of specific 
driver mutations has transformed the diagnosis and treatment of NSCLC.
With the development of sequencing technology and bioinformatics databases, researchers 
have identified that more than 90% of genome is transcribed; of these transcripts, most are 
non-coding RNAs with little or no protein-coding potentials [8]. The enormous number and 
complex kinds of non-coding RNAs have drawn peoples’ attention to their roles in biological 
processes. MicroRNA (miRNA) is a well-studied small non-coding RNA of 18–25 nucleotides 
[9]. The functions of miRNAs can be summarized as mediating gene silencing by interfering 
with translational process or inducing mRNA degradation [10, 11]. miRNAs can be classified 
into oncomiRNAs and tumour suppressor miRNAs in relation to their function in carcino-
genic processes; meanwhile, some of them show both oncogenic and suppressive activities 
under different situations [12]. Another advantage for miRNAs is their high stability and easy 
detection in tissue and blood [13, 14]. Several studies have reported the deregulation of vari-
ous miRNAs in NSCLC [13, 15]. Screening studies have uncovered the potential of miRNAs 
as biomarkers in the diagnosis and prognosis of NSCLC [16, 17]. As the researches for novel 
biomarkers and therapy targets go further, another class of non-coding RNA molecules, long 
non-coding RNAs (lncRNAs) with longer length and more complex biological functions have 
drawn people’s attentions and become a new star in the RNA world.
2. Long non-coding RNAs in non-small cell lung cancer
2.1. Long non-coding RNAs
The development of microarray and high-throughput sequencing technologies have enabled 
us to explore the RNA world. As the understanding of the heterogeneous RNA molecules 
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goes deeper, the functional RNA molecules gain increasing attention again, among these, 
lncRNAs play a major role in the centre stage. Long non-coding RNAs can be loosely defined 
as a class of non-coding RNA, which are longer than 200 nucleotides. Different from the 
small non-coding RNAs, although lncRNAs have little or no protein coding potentials, sev-
eral common features are still shared with mRNAs. Most of the lncRNAs are transcribed 
by RNA polymerase II, subsequent post-transcriptional processing including alternative 
splicing, 5′-capping, and polyadenylation are prevalently found in many lncRNAs [18]. Like 
mRNAs, the expression of lncRNAs is also under the regulation of transcriptional and epi-
genetic factors. Active or repressive histone marks that indicate the transcription status can 
also be found around the transcription start site of the lncRNAs [19]. On the other hand, 
lncRNAs have their own characters. LncRNAs have shorter median transcript length (2453 
nucleotides for mRNAs and 592 nucleotides for lncRNAs) and less median exons number (8 
exons for mRNAs and 3 exons for lncRNAs) than mRNAs [18]. Most lncRNAs are located 
in the nucleus, as most of them are functioned as regulation factors. The expression level of 
lncRNAs is always lower in cells than mRNAs, but with higher tissue specificities [18]. On the 
epigenetic level, the transcription start sites of lncRNAs have a higher density of DNA meth-
ylation compare with the mRNAs, however, this high methylation density is independent of 
their expression status [19].
The various features associated with mRNAs imply the complex origin and functions of 
lncRNAs. Study on the origin of lncRNAs are relatively scant, several hypotheses of the 
emergence of lncRNAs have been put forward. Some lncRNAs, such as Xist lncRNA, are 
believed to originate by undergoing a metamorphosis from erstwhile protein-coding gene 
while incorporating transposable sequence [20]. Other studies report the lncRNA can also 
originate from chromosome’s rearrangement, duplication of a non-coding gene by retro-
transposition, neighbouring repeat, or transposable elements insertion [21, 22]. Along with 
the complex originations, lncRNAs also have heterogeneous groups with multiple classifica-
tions. The most prevalent classification method is based on the genomic location and con-
text. According to this method, lncRNAs can be defined as: (1) sense lncRNAs; (2) antisense 
lncRNAs that are transcribed from the sense or antisense strands, respectively, overlapping 
one or more exons of protein-coding gene on the same or opposite strand; (3) bidirectional 
lncRNAs, whose transcription and neighbouring coding transcript on the opposite strand is 
initiated in close genomic proximity; (4) intronic lncRNA that are transcribed entirely from 
introns of protein-coding genes; (5) intergenic lncRNA that lies within the genomic interval 
between two genes [20, 23, 24]. Functions of lncRNAs may differ from each category. In gen-
eral, through molecular mechanisms like signalling, decoying, guiding, and scaffolding [25], 
lncRNAs are widely involved in gene progresses like chromatin modification, transcriptional 
regulation, and post-transcriptional regulation [26–29]. As the exploration of lncRNAs goes 
further, growing evidences demonstrate that lncRNAs play important roles in various cel-
lular processes [25, 30, 31]. Studies have identified the aberrant expression of lncRNAs in 
various cancers [32, 33] including non-small cell lung cancer [34]. The deregulation of some 
specific functional lncRNAs is proved to be important drivers implicated in tumour initializa-
tion and malignant transformation. Thus, lncRNAs have the potential as cancer biomarkers in 
the diagnosis and prognosis, as well as the targets for cancer therapy.
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2.2. Functional lncRNAs in NSCLC
According to the current version of GENCODE (encyclopaedia of genes and gene variants), 
15,767 long non-coding RNA genes encoding 27,692 long non-coding loci RNA have been 
identified based on manual curation, computational analysis, and experimental valida-
tion [35]. Along with it is the plethora of deregulated lncRNAs that are found in plenty of 
high-throughput lncRNA screen works. However, compared with the numerous screened 
lncRNAs, only few lncRNAs are well characterized and validated, the roles of most deregu-
lated lncRNAs in diseases still remained unknown, and the data on the mechanism are scarce. 
In this section, some well characterized lncRNAs with reported deregulation and associated 
pathophysiological functions in NSCLC are reviewed.
2.2.1. HOX transcript antisense RNA (HOTAIR)
HOX transcript antisense RNA (HOTAIR) is a 2158 bps long antisense lncRNA transcribed 
from human HOXC locus in chromosome 12q13 [36]. As one of the most well-studied lncRNA 
implicated in cancer, HOTAIR is mainly involved in the epigenetic regulation as a molecu-
lar scaffold. HOTAIR can interact with polycomb repressive complex 2 (PRC2) and lysine-
specific demethylase 1 (LSD1) in its 5′- and 3′-domain, respectively, and recruits PCR2 and 
LSD1 to the HOXD locus located on chromosome 2, inducing H3K27 methylation and H3K4 
demethylation, thus silences a gene cluster involved in metastasis suppression.
HOTAIR was first reported to be highly overexpressed in primary breast cancer and metastatic 
breast cancer tissues. The high expression level of HOTAIR in breast cancer was closely asso-
ciated with the metastasis [37]. A further study in the breast carcinoma cells showed that the 
enforced overexpression of HOTAIR led to the methylation of H3K27 [37]. Other researches 
also reported the up-regulated HORAIR as a negative prognostic predictor in hepatocellular 
carcinoma [38], colorectal carcinoma [39], pancreatic cancer [40], oesophageal carcinoma [41], 
lung cancer [42], and gastric cancer [43, 44]. In gastric cancer, HOTAIR was also reported as 
an endogenous sponge of miR-331-3p, thus abolishing repression of target gene HER2 [44].
In non-small cell lung cancer, Liu et al. analysed the HOTAIR expression level in 42 NSCLC 
tissues and 4 NSCLC cell lines and reported the high expression of HOTAIR in both NSCLC 
samples and cell lines compared with corresponding normal counterparts. Results showed 
that high expression level of HOTAIR was correlated with advanced disease stage, metastasis, 
and short disease free interval. Furthermore, knockdown of HOTAIR decreased the migration 
and invasion of NSCLC cells in vitro and impeded cell metastasis in vivo, without altering 
cell vitality, which suggests a potential therapeutic role of lncRNA targeted therapies [42]. 
Nakagawa et al. examined the expression of HOTAIR in 77 NSCLCs and 6 brain metastases. 
They confirmed the negative prognostic effects of HOTAIR high expression and pointed out 
the overexpression of HOTAIR enhanced the invasion of NSCLC cells [45]. In lung adenocar-
cinoma (ADC) cells, the upregulation of HOTAIR contributed to the cisplatin resistance of 
ADC cells through the regulation of p21 expression, and a silence of HOTAIR resulted in the 
increase of chemosensitivity, which further led to the inhibition of cell proliferation, induc-
tion of G0/G1 cell-cycle arrest and enhancement of apoptosis [46]. Another study of lung ADC 
found that HOTAIR was an important mediator for the ratio of FOXA1 and FOXA2, which 
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might infect the migration and invasion [47]. A tumour micro-environment study performed 
in a type I collagen (Col-1) supplemented three-dimensional organotypic culture model 
found that the expression of HOTAIR could be upregulated by the tumour-promoting Col-1 
in lung cancer cells. This finding provided a deeper insight into the mechanism of HOTAIR 
regulation [48].
In summary, various studies have worked on illuminating the mechanism of HOTAIR dereg-
ulation and function in NSCLCs. HOTAIR is widely involved in the chromatin modifica-
tions, and can also interact with various molecules like miRNAs and proteins. Although the 
facts that HOTAIR promotes cancer progress and drug resistance in NSCLC cells have been 
revealed, there are still many unclarified details in the mechanisms. Hence, more analyses on 
HOTAIR regulation and modes of action are needed.
2.2.2. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1)
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as nuclear-
enriched abundant transcript 2 (NEAT2), is an 8 kbs nuclear lncRNA expressed in chromo-
some 11q13 [49]. The mature MALAT1 transcript is generated through the procession by 
RNase P and RNase Z from the primary transcript [50]. MALAT1 is located in the nuclear 
speckles, and is mainly involved in alternative splicing process [51, 52]. MALAT1 exists 
widely and conservatively in lung, pancreas, and other healthy organs, the abundant amount 
of MALAT1 in these organs suggests significant functions for MALAT1 [49].
As one of the earliest identified cancer-associated lncRNAs, MALAT1 was firstly regarded 
as a high-risk predictor for metastasis in early stage NSCLC patients [49]. Since then, accu-
mulating evidences confirmed the negative prognostic factor of MALAT1 in various cancers. 
Overexpression of MALAT1 was identified in pancreatic cancers and colorectal cancers, the 
high expression level was correlated with clinical progression and poor prognosis [53, 54]. 
Upregulation of MALAT1 was reported to promote the proliferation and metastasis of osteo-
sarcoma and gallbladder cancer via different pathways such as PI3K/AKT and ERK/MAPK 
pathways [55, 56]. In oesophageal squamous cell carcinoma, silencing the MALAT1 expres-
sion resulted in the inhabitation of proliferation, migration, and invasion [57, 58]. Other stud-
ies also reported the deregulation of MALAT1 in bladder cancer and renal cancers [59, 60].
High expression of MALAT1 was identified in both early stage lung adenocarcinomas and 
squamous cell lung cancers [49, 61]. The overexpression of MALAT1 in NSCLC was reported 
to be associated with poor prognosis, shorter overall survival, and metastasis development. 
An RNAi-mediated suppression of MALAT1 performed in A549 cells led to the suppres-
sion of cell migration and clonogenic growth. Reversely, enforced upregulation of MALAT1 
resulted in an increased NSCLC cell growth and colony formation in vitro [61]. In a later 
study, a highly efficient knockdown of MALAT1 in a NSCLC cell line, through zinc finger 
nuclease-based technique, confirmed the MALAT1 positive influence on the cell metastasis 
in vitro and in vivo without affecting cell proliferation. Furthermore, blocking MALAT1 by 
antisense oligonucleotides (ASO) prevented the tumour metastasis formation in a tumour 
implanted mouse xenograft module, which provides a potential therapeutic approach to pre-
vent lung cancer metastasis [62].
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Numbers of studies have been performed on elucidating the mechanism of MALAT1 regu-
lation. Alternative splicing is one of the major topics in the MALAT1 functions. One exam-
ple was that MALAT1 could interact with some alternative splicing factors such as Serine/
Arginine (SR) proteins, thus affected the gene expression [52]. Another example in human 
diploid fibroblasts cell lines demonstrated the depletion of MALAT1 might led to the aberrant 
alternative splicing of the pre-mRNA of oncogenic transcription factor B-MYB, thus reduced 
the expression of it [63]. Another major topic is the gene expression regulation. MALAT1 dis-
played a strong association with genes involved in cellular growth, movement, proliferation, 
signalling, and immune regulation [61]. In lung cancer, MALAT1 could activate the expres-
sion of some metastasis-associated genes without affecting the alternative splicing [62]. A 
study involved in the epigenetic field reported that MALAT1 could interact with demethyl-
ated Polycomb 2 protein (Pc2), and controlled the re-localization of growth control genes 
between polycomb bodies and interchromatin granules [64].
In summary, the poor prognostic role and multiple functions of MALAT1 indicate its poten-
tial as predictable biomarker and therapy target. However, detailed studies are still needed as 
the mechanisms of MALAT1 regulation differ in various situations.
2.2.3. H19
H19 is a paternally imprinted and maternally expressed gene localized on human chromo-
some 11p15 [65]. Beside the H19 transcripts, the H19 locus also harbours miR-675, an anti-
sense transcript, and an antisense protein-encoding transcript [66]. H19 was first reported 
as a tumour suppressor gene in mice [65]. However, later studies point out the oncogenic 
potential of H19.
Loss of imprinting (LOI) in paternal allele and the resulting overexpression of H19 was found 
in various cancers including lung cancer [67], oesophagus cancer [68], osteosarcoma [69], 
and bladder cancer [70]. H19 upregulation was found related to a range of risk factors such 
as smoking, carcinogens exposuring, and hypoxia. Cigarette smoking could induce a LOI-
independent upregulation of H19 by activating the H19 maternal allele [71]. This observa-
tion was also confirmed in a later in vitro study, which reported the increased expression 
of H19 in human respiratory epithelial cells treated with cigarette smoking condensate [72]. 
Hypoxia could also induce upregulation of H19 in cell lines with mutated p53, through a 
critical factor HIF1-alpha [73]. H19 was also directly induced by MYC oncogene in different 
cell types including fibroblast cells. A study demonstrated that c-Myc selectively increased 
H19 transcription from the maternally derived allele, and downregulated the reciprocally 
imprinted gene insulin-like growth factor 2 (IGF2) at the H19/IGF2 locus. This study indicated 
that c-Myc and H19 expression had strong association in lung carcinomas [74]. The mineral 
dust-induced gene (MDIG) could conduct the demethylation of H3K9me3 in the promoter 
region of H19 and activate the H19 expression. High expression of MDIG and H19 were found 
correlated with poorer survival of the lung cancer patients [75].
In NSCLC, the expression levels of lncRNA H19 in tissues and cells were significantly higher 
than adjacent tissues and normal cells, overexpression and knockdown of c-Myc could change 
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the H19 expression level significantly. Moreover the higher expression of H19 was positively 
correlated with advanced tumour-node-metastasis (TNM) stage and tumour size [76].
In summary, the expression level of H19 is related to many risk factors including smoking, 
which is an important lung cancer factor. Overexpression of H19 may contribute to the cell 
proliferative in many cancers and is associated with poor prognosis. Since the deregulation of 
H19 expression may occur from different mechanism, future studies should focus on the dif-
ferent functions of H19 in physiological and pathological processes and evaluate the potential 
of H19 as biomarkers and therapy targets under different situations.
2.2.4. Cancer-associated region long non-coding RNA 5 (CARLo-5)
LncRNAs cancer-associated region long non-coding RNA 5 (CARLo-5) is transcribed from 
the (−) strand of the 8q24.21 genomic region, where two other transcripts, sharing significant 
overlap in their sequences, colon cancer-associated transcript 1 (CCAT1) and CCAT1 long 
isoform (CCAT1-L) are also transcribed [66].
CARLo-5 was originally reported to be overexpressed in colorectal cancer patient tissues [77]. 
Later study revealed the overexpression of CARLo-5 in NSCLC and in some other cancers 
such as gastric cancer [78, 79]. In NSCLC patients, high CARLo-5 expression level was asso-
ciated with advanced pathological stage and lymph node metastasis and was a significant 
predictor of shorter overall survival. An in vitro knockdown experiment showed a significant 
inhibition of proliferation in tumour cells, mainly due to the induction of the G0/G1 arrest [77, 
78]. Furthermore, silencing CARLo-5 could result in the inhibitory effects in the cell invasion 
and migration, possibly by modulating the EMT process [78].
The regulatory mechanism of CARLo-5 may be related to the adjacent region of the can-
cer-associated variant rs6983267, as the region including rs6983267 has enhancer activity 
and can interact with the proto-oncogene MYC [80]. Evidences were provided in a colon 
cancer study that demonstrated a strong connection between the cancer-associated variant 
rs6983267 and the expression of CARLo-5. The chromosome conformation capture method 
revealed the MYC enhancer region could physically interact with the active regulatory region 
of the CARLo-5 promoter and enhanced the expression of CARLo-5, this finding suggested 
there was a long-range interaction of MYC enhancer with the CARLo-5 promoter [77]. Since 
CARLo-5 is proved to have an oncogenic function, further studies focus on elucidating the 
mechanism of CARLo-5 regulation may provide potential therapy target for cancer treatment.
2.2.5. Other functional lncRNAs in NSCLC
LncRNA colon cancer-associated transcript 2 (CCAT2) is expressed from a highly conserved 
MYC enhancer region within chromosome 8q24.21. It was initially reported to be involved 
in metastatic progress and chromosome instability in colorectal cancer [81]. Further studies 
reported its association with poor prognosis in various cancers including NSCLC [82]. CCAT2 
was significantly overexpressed in NSCLC tissues, in particular, the overexpression of CCAT2 
was associated with adenocarcinomas specifically but not with squamous cell carcinoma. 
Long Non-Coding RNA in Non-Small Cell Lung Cancers
http://dx.doi.org/10.5772/66487
185
Silencing CCAT2 by siRNA led to the inhibition of proliferation and invasion in NSCLC cell 
lines in vitro, supporting the role of CCAT2 in the metastatic progression. Further analysis 
found that CCAT2 combined with CEA could predict lymph node metastasis. These findings 
implied the potential of CCAT2 as a specific ADC biomarker for lymph node metastasis.
Growth arrest-specific transcript 5 (GAS5) is expressed from human chromosome 1q25 [83]. 
GAS5 was found significantly downregulated in NSCLC tissues, which was correlated with 
advanced TNM stage and increased tumour size [84]. GAS5 could compete with the gluco-
corticoid response elements (GRE) on DNA by directly interacting with the DNA-binding 
domain of glucocorticoid receptor (GR), thus prevented the activation of glucocorticoid-
responsive genes. This competition resulted in the reduction of cell growth and metabolism, 
while sensitizing cells to apoptosis [85]. Recent study demonstrated that downregulation of 
GAS5 was associated with cisplatin resistance in NSCLC. GAS5 could inhibit autophagy and 
therefore enhance cisplatin sensitivity in NSCLC cells [86]. Another study found that GAS5 
overexpression was inversely correlated with EGFR pathway and the expression of IGF-1R 
proteins in human ADC cell line, indicating its role in reversing EGFR-TKIs resistance [87]. 
These findings indicate the tumour suppressor lncRNA GAS5 may represent a potential bio-
marker for diagnosis and therapy target for NSCLC intervention.
SRY-box containing gene 2 overlapping transcript (SOX2OT) locates in the chromosome 
region 3q26.33, and is transcribed form the same orientation of gene SOX2 [88]. SOX2OT 
was reported upregulated in NSCLC, along with the upregulation of SOX2, meanwhile, the 
expression level was significantly higher in lung SCCs than ADCs [89]. Further study found 
high SOX2OT expression predicted poor survival in lung cancer patients. In lung cancer cell 
lines, knocking down SOX2OT inhibited the cell proliferation. These finding suggest the 
oncogenic SOX2OT may be prognostic indicator for NSCLC [89].
BRAF-activated non-coding RNA (BANCR) is a 693 bps lncRNA located on (−) strand of chro-
mosome 9q21, which is initially found as a tumour suppressor factor involved in melanoma 
cell migration [90]. BANCR expression level was reported to be significantly decreased in 
NSCLC tumour tissues samples, the reduction of BANCR was related to the larger tumour 
size, advanced TNM stage, metastasis development, and shorter overall survival. BANCR 
was also an independent poor prognostic predictor of poor survival for NSCLC. An inves-
tigation on the mechanisms of tissue-specific expression revealed that histone deacetylase 
might be involved in the repression of BANCR. Furthermore, upregulation of BANCR inhib-
ited NSCLC cell viability, migration, and invasion, while promoting the apoptosis process. 
Reversely, knockdown of BANCR promoted migration and invasion of NSCLC cells in vitro. 
These inhibitory effects were reported to be associated with EMT [91]. Interestingly, although 
BANCR was downregulated in NSCLC, some studies reported the significant upregulation 
of BANCR in other cancers, which suggested a tissue-dependent regulation mechanism of 
BANCR [66].
Maternally expressed gene 3 (MEG3) is expressed in chromosome 14q32.3 with a full length 
of 1.6 kb nucleotides [92]. Alternative splicing process was found associated with the gene 
MEG3, which consisted of 10 exons and could generate multiple transcripts [93]. It was 
reported that the expression level of MEG3 in NSCLC tissues was significantly lowered than 
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normal tissues, which might due to the higher methylation rate of MEG3-DMR in NSCLC 
cells. Downregulation of MEG3 in NSCLC patients was associated with poor prognosis. In 
addition, overexpression of MEG3 by transfecting exogenous pCDNA-MEG3 into NSCLC 
cells inhibited cell proliferation and induced cell apoptosis in vitro, partially through activat-
ing the p53 signalling pathway [94].
3. Long noncoding RNA as novel NSCLC biomarkers
The high mortal rate of NSCLC may be mainly attributed to the late diagnosis and tumour 
metastasis. In addition, the heterogeneity of disease also increases the difficulty in the diagno-
sis and treatment, the molecular characters are different from each subtypes. Early detection, 
precise diagnosis, and treatment may increases the survival rate of NSCLC. To meet these 
ends, it is of great importance to identify novel NSCLC biomarkers.
As a new class of functional RNA molecules, lncRNAs are involved in a wide range of cel-
lular and biological processes. Dysregulation of lncRNAs is associated with many cancer-
related processes. In addition, the expression of lncRNA can be very tissue specific. These 
advantageous features imply a potential role of lncRNAs in cancer detection and treatment. 
Reduced BANCR expression was found to be an independent prognostic factor for NSCLC 
[91]. Huang et al. found small amount of lncRNAs (3.36%) in circulating vesicles [95]. Later 
research detected lncRNA HOTAIR, MALAT1, and H19 in the plasma of patients with gastric 
cancer and identified the expression level of plasma H19 was significantly higher than nor-
mal samples, furthermore, plasma H19 level was reduced in postoperative samples, which 
suggested H19 might be a biomarkers for gastric cancer [96]. Ren et al. identified fragments 
of lncRNA MALAT1 in plasma of prostate cancer (Pca) and named one of them as MALAT1-
derived miniRNA (MD-miniRNA). Researchers then evaluated the diagnostic performance of 
MD-miniRNA in plasma samples of 192 patients. The results showed a sensitivity of 58.6% 
and specificity of 84.8% for discriminating PCa from non-PCa [97]. Although the functional 
lncRNAs mentioned above have been well-characterized, only few of them have been evalu-
ated as biomarkers for diagnosis and prognosis in NSCLC, further validations is still need.
With the development of high-throughput technology, an increasing number of previously 
unidentified lncRNAs have been found. More and more researchers started to explore novel 
biomarkers from these unidentified lncRNAs. MiTranscriptome is a database, which derived 
from computational analysis of high-throughput RNA sequencing (RNA-Seq) data compris-
ing 6500 samples spanning diverse cancer and tissue types. In database, 1128 ADC-related 
lncRNAs and 1309 lung SCC-related lncRNAs are identified, among these, 4 lncRNAs in ADC 
and 11 lncRNAs in lung SCC are predicted to be tissue specific, indicating that lncRNAs can 
discriminate not only between tumour and normal samples, but also between different sub-
types [98]. Although most of these lncRNAs remain to be annotated and validated, the large 
number of cancer-related lncRNAs provides great hope for further screening of biomarkers 
and therapy targets. Some groups have investigated the potential of lncRNAs as biomark-
ers in early detection of NSCLCs. Wang et al. examined the expression of lncRNAs in three 
pairs of early stage ADC samples by high-throughput microarray technology and identified 
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LncRNA Regulation Region p-Value AUC Sensitivity (%) Specificity (%) Type of sample Reference
BC034684 Up Chr1:203,148,063–
203,148,611
1.486E−06 0.719 79.4 60.3 Tissue Wang et al. [99]
RP11-1008C21.2 Down Chr15:38,363,827–
38,364,884
1.193E−07 0.843 81 79.4
AK094413 Down Chr9:104,235,441–
104,237,132
6.634E−08 0.821 85.2 62.4
RP11-598F7.5 Down Chr12:273,829–275,487 4.108E−11 0.882 79.4 84.1
VNN2 Down Chr6:133,065,008–
133,079,022
1.063E−05 0.835 77.8 79.4
Combination 0.987 92 98
SPRY4-IT1 Up Chr5:142,317,620–
142,318,322
<0.01 0.603 / / Plasma Hu et al. [102]
ANRIL Up Chr9:21,994,791–
22,120,646
<0.001 0.798 / /
NEAT1 Up Chr11:65,422,800–
65,423,368
<0.001 0.693 / /
Combination 0.876 88 81
MALAT1 Up Chr11:65,497,762–
65,506,469
<0.0001 0.79 56 96 Peripheral blood Weber et al. [101]
Table 1. List of NSCLC-associated lncRNA biomarkers identified in different researches.
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1170 differentially expressed lncRNAs (DE-lncRNAs) between early stage ADC tissues and 
their adjacent normal tissues. Further analysis identified 20 candidates of lncRNAs from 
1170 DE-lncRNAs through a screening pipeline, the pipeline could be summarized briefly as 
follows: if an lncRNA’s average inter-group difference between tumour group and normal 
group was 10 times bigger than the inner group difference, it would be selected as a candi-
date. These 20 candidates were then validated by real-time quantitative PCR (qPCR) on a 
total of 102 pairs of early stage ADC samples. A panel of five lncRNAs (Table 1) was finally 
identified which can distinguish early stage adenocarcinoma samples from normal samples 
with high sensitivity (97%) and specificity (92%) [99]. Another study, which integrated two 
NSCLC microarray datasets comprising 165 and 90 patients, reported a list of 64 significantly 
deregulated lncRNAs in NSCLC tumours compared with normal lung tissues and a panel of 
181 lncRNAs that were specific to histological subtypes of NSCLC [100].
An ideal biomarker should be of high sensitivity and specificity, and it should be easy to detect, 
better with non-invasive methods from body liquids. Weber et al. detected the expression 
level of MALAT1 in the cellular fraction of blood of a small NSCLC patients group (Table 1), 
they found that MALAT1 was detectable in peripheral human blood and the expression level 
between cancer patients and cancer-free controls was different, the sensitivity and specificity 
for discrimination was 56% and 96%, respectively [101]. Another study reported circulating 
SPRY4-IT1, ANRIL, and NEAT1 were significantly increased in plasma samples of NSCLC 
patients (Table 1). Combination with the three factors indicated a high power of discrimina-
tion (AUC, 0.876; sensitivity, 82.8%; and specificity, 92.3%) [102].
4. Conclusion
Since the researchers have identified that most of the genome is actively transcribed, while 
only small part of the human genome has the coding potential as protein-coding genes, the 
roles of non-coding RNAs have been transferred from transcriptional noises to the important 
functional molecules. This finding has led the classical view of the central dogma, which con-
siders that the RNA functions mainly as an intermediate bridge between DNA sequences and 
protein synthesis, into a deeper understanding.
The roles of lncRNAs in the upstream of whole cellular signal system indicate that lncRNAs 
are closely associated with cellular differentiation, mitosis, and apoptosis. In the view of epi-
genetics, the functions of lncRNAs are mainly involved in three levels, including chromatin 
remodelling, transcriptional control, and post-transcriptional processes. LncRNA can act as 
transcriptional regulators and modulate the expression of protein-coding genes in cis or trans 
manner through directly or indirectly binding to DNA or protein molecules. Thus, the occur-
rences of diseases including cancers are always along with the dysregulation of lncRNAs. In 
this chapter, we have discussed several lncRNAs that have been reported to be associated 
with NSCLCs. Some of them are well-characterized and also identified in other cancers, while 
some still remain to be studied. Most of these lncRNAs have the potential as biomarkers in 
diagnosis and prognosis of NSCLCs. However, these lncRNAs lack NSCLC tissue specificity, 
thus great efforts are still needed to identify NSCLC tissue-specific lncRNAs.
Long Non-Coding RNA in Non-Small Cell Lung Cancers
http://dx.doi.org/10.5772/66487
189
Despite the high performance of these lncRNA panels in diagnosis, most of them are identi-
fied from statistical analysis, which means the biological meanings of lncRNAs have not been 
taken into consideration. In addition, the candidate screening methods are mainly based on 
p-value, fold change, absolute expression level, and PAM method, outcomes of the candidates 
may differs for different methods [103]. Thus, a better candidate screening method combining 
the biological meaning of lncRNAs and robust statistical pipeline is need for future stud-
ies. Also, up to now, most of the samples in these studies are collected from patient tissues 
through invasive methods, more works are still needed to explore circulating lncRNA expres-
sions in blood plasma, urine, or sputum, which can meet the non-invasive demands.
Considering the sophisticated functions and large number of lncRNAs, we have now iden-
tified just the tip of the lncRNA iceberg. Lots of questions are waiting to be clarified, for 
example, what does the classification of lncRNAs looks like, and what the mechanistic basis 
of their functions is. Huge gaps are still in front of us in understanding the big picture of 
the lncRNA world. Fortunately, new technology such as the third generation sequencing, 
which allows the longer read length, are now providing more reliable and accurate informa-
tion of lncRNAs. In future, we believe that understanding the lncRNA world will bring us 
new answers to old questions in evolution, development, and the understanding of NSCLCs. 
There may be a long way before the clinical application of lncRNAs in NSCLC, however, fast 
progressing in the lncRNA filed opens up numerous opportunities for diagnosis and thera-
peutic intervention against NSCLC.
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